IE 11 is a very old Browser and it`s not supported on this site
Financial Report Consolidated financial statements

Consolidated balance sheet as at December 31 

in CHF 1 000

 

Notes

 

2021

 

2020

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

2 835

 

6 816

Receivables from brokers

 

 

 

 

1 521

Securities

 

4

 

3 641 112

 

3 954 659

Other assets

 

 

 

135

 

139

 

 

 

 

3 644 082

 

3 963 135

Total assets

 

 

 

3 644 082

 

3 963 135

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Short-term borrowings from banks

 

5

 

355 000

 

63 000

Payables to brokers

 

 

 

 

6 576

Other short-term liabilities

 

6

 

5 431

 

5 709

Tax liabilities

 

 

 

158

 

303

 

 

 

 

360 589

 

75 588

Total liabilities

 

 

 

360 589

 

75 588

 

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

Share capital

 

7

 

11 080

 

11 080

Treasury shares

 

7

 

(9 205)

 

(8 241)

Retained earnings

 

7

 

3 281 618

 

3 884 708

 

 

 

 

3 283 493

 

3 887 547

Total liabilities and shareholders' equity

 

 

 

3 644 082

 

3 963 135

 

 

 

 

 

 

 

Net asset value per share in CHF

 

 

 

59.40

 

70.30

The notes are an integral part of the consolidated financial statements.

The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on February 15, 2022.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer